Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-504 in ALK-positive NSCLC
NCT01228435Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2010
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of retaspimycin in non-small cell lung cancer (NSCLC), sponsored by Massachusetts General Hospital. Started Oct 2010; status: terminated.
02
Drugs
retaspimycin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01228435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01228435.